Roy S. Herbst, MD, PhD:In my practice, which is an exclusive lung practice, you can imagine that I see many patients who have chemotherapy-refractory disease. And certainly, in those patients who are nonsquamous, such as the one we’re discussing today, who’ve already had pemetrexed, your second-line choice of chemotherapy is docetaxel. Certainly, you have the choice of whether to give a docetaxel-based combination, docetaxel alone, or immunotherapy. Many people are going right to the immunotherapy now, just because the curves overlap for the 2, even in PD-L1negative patients, and the side effects are perhaps less. I think that’s true. That has been my experience for immunotherapy and then chemotherapy.
Now, in most cases, people would give immunotherapy in the second-line and save the second-line chemotherapy, so to speak, the docetaxel, for third-line use. My experience with the docetaxel/ramucirumab regimen has been in immuno-oncologynaïve and immuno-oncology–treated patients. It has been available to us for almost 3 years now, and was also available before that in clinical trials. I’ve used it in both cases.
I think it’s a well-tolerated regimen. It doesn’t add much to the docetaxel. It can be used in squamous and nonsquamous tumors. There are not many issues with bleeding. My sense is that it improves the outcomesthe response rates, progression-free survival, and overall survival, as shown in the REVEL trial.
We must not forget that we still have chemotherapy to offer. Immunotherapy’s all the rage, and we’re using a great deal of it at Yale right now. In fact, if patients can’t get immunotherapy as standard care in the frontline setting, they’re getting immunotherapy in some sort of clinical trial. But do you know what? Most of what I see, on a day-to-day basis, in the clinic are patients who are failing immunotherapy. Only 18% to 20% of patients, in 5 years, are doing great on immunotherapy, which is a phenomenon. Who would have thought we’d see metastatic disease at 5 years, at 20%? That means 80% of the patients are either primary refractory to immunotherapy, or they get immunotherapy and they become resistant.
My experience has been that about half of those patients that you treat with immunotherapy become resistant. At that point, we need another agent. You need new targeted agents, such as ones that targetVEGF. You need another chemotherapy. For the patient who has had immunotherapy and is progressing, you have to make a change. That’s where I would look to a docetaxel/ramucirumab combination, as we’re talking about here. This is in a little bit of a different order from how I would treat the case today. It will probably be different in a week from now, after new data emerge. That’s how quickly this field is moving. That’s why it is really important to stay on top of the most recent data.
Transcript edited for clarity.
Case: A 62-Year-Old Man With NSCLC and Bone Metastases
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More